Voyageur Pharmaceuticals Ltd V.VM

New info?

[lscfa]

https://stockhouse.com/news/newswire/2024/10/03/one-best-venture-pharma-stocks-has-grown-even-stronger

 

Additional products in development

Voyageur has four additional products at late stages of development:

• Vision HD 98 per cent: High-density (98 per cent weight-per-weight (w/w)) barium sulfate powder for upper GI double-contrast radiographic examinations.
• Vision LD 96 per cent: Versatile high-density (57 per cent w/w to 156 per cent w/w) barium sulfate powder for single contrast radiographic examinations of the upper and lower GI tract.
• Smooth HD 105 per cent: High-density (105 per cent weight-by-volume (w/v), 58 per cent w/w) barium sulfate suspension for upper GI esophagogram and double contrast studies.
• Smooth LD 60 per cent: Low-density (60 per cent w/v) barium sulfate suspension solution for single contrast radiographic examinations of the esophagus, stomach, and small bowel.

[postie1]

VM just has too much going for it to be sitting at this share price. Do not forget that the projections were at a much lower price and a conservative share of market. If tese new contrast agents work out what might the % of market share be? Also that Latin America deal was just for SmoothX 2%.. I hope we are all well rewarded for our patience.

[JrOGInvestor]

The real value of this company will be unlocked soon after news breaks of a Letter of Intent with another pharma company or suitable suitor. How much it moves will depend on a few things like who the 'dance partner' is as that could also speed up getting into the US market. Even if it doesn't, they have the opportunity to reach globally as last counted there are roughly 25 countries